RIO Study Suggests Antibodies Could Offer a Break from Daily HIV Treatment
The RIO study, a randomized, placebo-controlled clinical trial, found that a combination of two broadly neutralizing antibodies (bNAbs) effectively delayed viral rebound, after stopping ART, raising hopes for more flexible treatment options.